Skip to main content
SpringerLink
Log in

Insulin Sensitizers and Heart Failure: An Engine Flooded with Fuel

  • Clinical Trial Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Medical Officer’s Review of New Drug Application 21-071–Rosiglitazone (AVANDIA). Center for Drug Evaluation and Research, US Food and Drug Administration, 1999. http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21071_Avandia_medr.pdf. Accessed September 17, 2010.

  2. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  CAS  PubMed  Google Scholar 

  3. US Food and Drug Administration: Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Briefing Document 30 July 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf. Accessed September 17, 2010.

  4. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125–2135.

    Article  CAS  PubMed  Google Scholar 

  5. Nissen SE: The rise and fall of rosiglitazone. Eur Heart J 2010, 31:773–776.

    Article  CAS  PubMed  Google Scholar 

  6. Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010 June 28 (Epub ahead of print).

  7. Benbow A, Stewart M, Yeoman G: Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ 2001, 322:236.

    Article  CAS  PubMed  Google Scholar 

  8. Lincoff AM, Wolski K, Nicholls SJ, et al.: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.

    Article  CAS  PubMed  Google Scholar 

  9. Aguilar D, Bozkurt B, Ramasubbu K, et al.: Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009, 54:422–428.

    Article  CAS  PubMed  Google Scholar 

  10. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  CAS  PubMed  Google Scholar 

  11. Kalantar-Zadeh K, Block G, Horwich T, et al.: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43:1439–1444.

    Article  PubMed  Google Scholar 

  12. Jagasia D, Whiting JM, Concato J, et al.: Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001, 103:1734–1739.

    CAS  PubMed  Google Scholar 

  13. Kolka CM, Harrison LN, Lottati M, et al.: Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle. Diabetes 2010, 59:619–626.

    Article  CAS  PubMed  Google Scholar 

  14. Taegtmeyer H, Hems R, Krebs HA: Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980, 186:701–711.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank Ms. Roxy Tate for her excellent editorial assistance.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Texas Medical School at Houston, 6431 Fannin, MSB 1.246, Houston, TX, 77030, USA

    Khaled I. Khalaf & Heinrich Taegtmeyer

Authors
  1. Khaled I. Khalaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinrich Taegtmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heinrich Taegtmeyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khalaf, K.I., Taegtmeyer, H. Insulin Sensitizers and Heart Failure: An Engine Flooded with Fuel. Curr Hypertens Rep 12, 399–401 (2010). https://doi.org/10.1007/s11906-010-0158-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-010-0158-7

Keywords

Search

Navigation